Physician Views Preview: Bayer’s Kerendia approved for CKD in US

US physicians treating chronic kidney disease (CKD) in patients with diabetes have recently had two new therapies added to selection they can choose from.

In April, the FDA approved AstraZeneca’s SGLT-2 inhibitor Farxiga in this setting (and simultaneously to treat CKD in patients without diabetes) and earlier this month the agency approved Bayer’s oral, non-steroidal mineralocorticoid receptor (MR) antagonist Kerendia.

Some experts have said Farxiga will benefit in CKD not only from its impressive clinical data but a ‘halo effect’ as this drug class continues to rack up wins in other indications (Eli Lilly and Boehringer Ingelheim’s Jardiance just hit its primary endpoint in a Phase III study for the notoriously challenging indication of heart failure with preserved ejection fraction [HFpEF]).

See ViewPoints: Bayer’s Kerendia could be a slow burner in CKD

To get a better idea of how these two therapies may evolve the treatment of CKD in diabetes patients we are running a snap-poll to US endocrinologists and general practitioners asking them the following questions…

  • Whether they have prescribed Farxiga or whether they intend to (and if so, when)
  • In what line of therapy they would anticipate using Farxiga most frequently
  • Whether they intend to prescribe Kerendia (and if so when)
  • In what line of therapy they would anticipate using Kerendia most frequently
  • How they anticipate use of Farxiga and Kerendia evolving in relation to each other (and whether combination use is realistic)

Results and analysis will be published later this week for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers. To be notified when they become available, click here

To read more Physician Views articles, click here.